Arbutus Biopharma
ABUS
ABUS
167 hedge funds and large institutions have $626M invested in Arbutus Biopharma in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 48 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
3% less funds holding
Funds holding: 172 → 167 (-5)
20% less call options, than puts
Call options by funds: $2.67M | Put options by funds: $3.34M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
167
Holding in Top 10
3
Calls
$2.67M
Puts
$3.34M
Top Buyers
| 1 | +$26.1M | |
| 2 | +$22.1M | |
| 3 | +$17.3M | |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$9.96M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$8.28M |
Top Sellers
| 1 | -$9.98M | |
| 2 | -$7.32M | |
| 3 | -$4.75M | |
| 4 |
Morgan Stanley
New York
|
-$3.55M |
| 5 |
SCM
Saba Capital Management
New York
|
-$1.67M |
